| Literature DB >> 34532060 |
Eric Lewitus1, Eric Sanders-Buell1, Meera Bose1, Anne Marie O'Sullivan1, Kultida Poltavee1, Yifan Li1, Hongjun Bai1, Thembi Mdluli1, Gina Donofrio1, Bonnie Slike1, Hong Zhao2, Kim Wong2, Lennie Chen2, Shana Miller1, Jenica Lee1, Bahar Ahani1, Steven Lepore1, Sevan Muhammad1, Rebecca Grande1, Ursula Tran1, Vincent Dussupt1, Letzibeth Mendez-Rivera1, Sorachai Nitayaphan3, Jaranit Kaewkungwal3, Punnee Pitisuttithum4, Supachai Rerks-Ngarm5, Robert J O'Connell3, Holly Janes6, Peter B Gilbert6, Robert Gramzinski1, Sandhya Vasan1, Merlin L Robb1, Nelson L Michael7, Shelly J Krebs1, Joshua T Herbeck8, Paul T Edlefsen6, James I Mullins2, Jerome H Kim1, Sodsai Tovanabutra1, Morgane Rolland1.
Abstract
The scale of the HIV-1 epidemic underscores the need for a vaccine. The multitude of circulating HIV-1 strains together with HIV-1's high evolvability hints that HIV-1 could adapt to a future vaccine. Here, we wanted to investigate the effect of vaccination on the evolution of the virus post-breakthrough infection. We analyzed 2,635 HIV-1 env sequences sampled up to a year post-diagnosis from 110 vaccine and placebo participants who became infected in the RV144 vaccine efficacy trial. We showed that the Env signature sites that were previously identified to distinguish vaccine and placebo participants were maintained over time. In addition, fewer sites were under diversifying selection in the vaccine group than in the placebo group. These results indicate that HIV-1 would possibly adapt to a vaccine upon its roll-out.Entities:
Keywords: HIV-1; sieve analysis; vaccine; within-host evolution
Year: 2021 PMID： 34532060 PMCID： PMC8438874 DOI： 10.1093/ve/veab057
Source DB: PubMed Journal: Virus Evol ISSN： 2057-1577